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ABSTRACT 
Background: Antimicrobial resistance among Candida species is an intense public health concern. The aim of the study was to 
determine the antifungal susceptibility pattern and test for cure of Candida species among women of child bearing age who 
visited the General Hospital Onitsha, Nigeria with symptoms suggestive of Vulvovaginal Candidiasis (VVC). 
Materials and Methods: Eight hundred and seventy six female patients participated in the study of which high vaginal swabs 
were collected and evaluated mycological by standard microbiological methods: microscopic examination and culture using 
sabouraud dextrose agar (SDA). Susceptibility of isolates to 4 antifungal agents was tested using agar dilution method. Clinico- 
mycological evaluation was also performed among the patients. 
Result: Higher minimum inhibitory concentration (MIC) to azole antifungals was observed predominantly among non-albicans 
Candida species increasingly involved in VVC. The rate of mycological resolution was higher than symptomatic relief at 2 
weeks after treatment with antifungal drug. 
Conclusion: Efficacious treatment of VVC requires an adequate knowledge of the causative agents and more importantly the 
antimicrobial to which they exhibit high susceptibility.  
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ABSTRAIT                                                                                                                                                                                                                                
Contexte: La résistance aux antimicrobiens chez les espèces de Candida est un problème de santé publique intense. L'objectif de 
l'étude était de déterminer le schéma de susceptibilité aux antifongiques et le test de guérison des espèces de Candida parmi les 
femmes en âge de procréer qui ont visité l'hôpital général de Onitsha, au Nigeria, avec des symptômes suggérant une candidose 
vulvovaginale (VVC).                                                                                                                                                                                                                                        
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Matériaux et méthodes: huit cent soixante-seize six patientes ont participé à l'étude des prélèvements vaginaux élevés collectés 
et évalués par mycologie par méthodes microbiologiques standard: examen microscopique et culture à l'aide de la gélose 
sabouraud dextrose (SDA). La susceptibilité des isolats à 4 agents antifongiques a été testée en utilisant une méthode de 
dilution en agar. Une évaluation clinico-mycologique a également été réalisée chez les patients. 
Résultat: une concentration minimale minimale d'inhibition (MIC) en anatoxines azoliques a été observée principalement chez 
les espèces non-albicans Candida de plus en plus impliquées dans VVC. Le taux de résolution mycologique était plus élevé que 
le soulagement symptomatique à 2 semaines après le traitement par un médicament antifongique. 
Conclusion: Un traitement efficace de la VVC nécessite une connaissance adéquate des agents causaux et, plus important 
encore, des antimicrobiens auxquels ils présentent une forte susceptibilité. 
Mots-clés: Candidiase Vulvovaginale, Clinico-mycologie, Résistance Antimicrobienne, Espèces Candida 
INTRODUCTION                                                             
Antimicrobial resistance among Candida species 
involved in Vulvovaginal candidiasis (VVC) 
continues to thrive as a serious public health concern. 
Vulvovaginal candidiasis is a conventional 
gynecological opportunistic mycological infection 
caused by Candida species in the lower genital tract 
among females globally [1,2]. It has been ascertained 
that approximately 75 % of sexually active females 
have a minimum of one-time experienced 
symptomatic VVC [3].  
The rise in incidence of fungal infection has resulted 
in an extensive use of antifungals [4] and the 
treatment is often carried out entirely on pragmatic 
basis, because vaginal cultures are not routinely 
taken, and susceptibility testing is scarcely done. 
Successful treatment of infections requires adequate 
information of the specific causative agent(s) and the 
drugs to which they are susceptible. Information 
available in the literature suggests that data on 
etiologic pattern in VVC and susceptibility to 
antifungal are lacking in Anambra State of Nigeria, 
particularly Onitsha, which is the commercial 
mainstay of the state. 
Antifungal susceptibility testing provides an 
evaluation of antifungal efficacy, guaranteeing good 
treatment outcome, limiting the development of drug 
resistance and therapeutic ability of unendorsed 
composites [5-7]. 
MATERIALS AND METHODS 
Study Population                                                                 
The present study took place between 2008 and 2009 
at an Obstetrics and Gynecology Department at 
General Hospital Onitsha, Nigeria. A total of 876 
women of different age groups were included in this 
study.  
Ethical Consideration 
Ethical approval of the study was sought from the 
Nnamdi Azikiwe University Teaching Hospital 
Institutional Review and Ethics Committee in Nnewi, 
Nigeria. Written consent was sought from the study 
subjects before inclusion into the study. 
Collection of Clinical Samples 
The sample: high vaginal swab was obtained for the 
study. The samples were collected by the clinician 
from the posterior fornix of the vagina with sterile 
Dacron cotton swab stick after dilation using a sterile 
speculum. Two swab samples were collected per 
subject. 
Microscopic Examination 
The first vaginal swab was rolled in drop of 
potassium hydroxide (KOH) then covered with cover 
slip. The slide was mounted on a microscope and 
examined using 10x and 40x objective.   
Isolation and Identification 
The second vaginal swab was inoculated onto 
Sabouraud dextrose agar (SDA) and incubated at 
370C and examined for growth daily for 4 days. 
Clinico-mycological Evaluation 
The patients with Candida positive cultures were 
asked to come back to the hospital after two weeks of 
treatment with antifungal drugs recommended to 
them. At the follow-up visit, the same questionnaire 
was administered and another vaginal swab was 
collected and processed as done previously. Clinico-  
mycological evaluation was then carried out using the 
following rating scale:  
A. Symptom absent, culture negative = very 
good = 3 point score 
B. Symptom present, culture negative = Good = 
2 point score 




D. Symptom present, culture positive = poor = 
0 point score 
Antifungal Susceptibility Testing 
Susceptibility of the isolates to antifungal drugs was 
carried out by agar dilution technique [8] using the 
following antifungal drugs: Fluconazole powder 
(Medich Plc, England); Itraconazole powder (Hanmi 
Pherm, Kore); Miconazole powder (Janssen 
Pharmaceutical Beerse Belgium); Clotrimazole 
powder (Symnedic Laboratories) as follows: 
i. Preparation of stock solution of antifungal 
drugs: 
  Stock solution of each of the drugs was 
prepared by dissolving 25.6mg of the powder in 
100ml of sterile 1: 9 dilution (in distilled water) of 
Dimethyl sulphoxide, to give 100ml of 256 µg/ml. All 
the stock solutions were sterilized by tyndalization. 
ii Agar Dilution Technique: 
Double strength SDA was prepared and dispensed 
into McCartney bottles in 10ml amounts and 
sterilized by autoclaving at 1210C for 15 min, and 
allowed to cool to about 450C. Two fold serial dilution 
of each of the drugs was subsequently made, in the 
molten agar, according to the protocol in table 1. The 
dilutions were up to 15th dilution (i.e. 0.008 - 
128µg/ml). The content of each McCartney bottle was 
thoroughly mixed and poured into plate and was 
allowed to set. 
 
Table 3: PROTOCOL FOR THE DILUTION OF ANTIFUNGAL DRUGS IN CULTURAL MEDIA 
      Tube        Vol. of Medium            Vol. of Drug Soln*             Vol. of Water                   Final Conc. 
       No 
1.         10 ml                                 10 ml                                   0.000ml                        128 µg/ml 
2.         10ml                                    5ml                                    5.00ml                             64 µg/ml 
3.         10 ml                                2.5ml                                    7.500ml                           32 µg/ml 
4.         10 ml                                1.25ml                                  8.750ml                           16 µg/ml 
5.         10 ml                                0.625ml                                9.375 ml                            8 µg/ml 
6.         10 ml                                0.3125ml                              9.688ml                             4 µg/ml 
7.         10ml                                 10ml                                     0.00ml                               2 µg/ml 
8.         10ml                                  5ml                                      5.00ml                               1 µg/ml 
9.         10ml                                 2.5ml                                    7.500ml                          0.5 µg/ml 
10.         10ml                                 1.25ml                                  8.750ml                          0.25 µg/ml 
11.        10ml                                  0.62ml                                 9.375ml                           0.125 µg/ml 
12.        10ml                                  0.3125ml                             9.688ml                           0.0625 µg/ml 
13.        10ml                                  10ml                                    0.00ml                             0.032 µg/ml 
14.        10ml                                    5ml                                    5.00ml                             0.016 µg/ml 
15.        10ml                                 2.5ml                                    7.500ml                           0.008 µg/ml 
* Stock solutions used were: Stock solution A(Conc = 256 µg/ml) – for dilution 1-6; Stock solution B (Conc = 4 µg/ml) – for 








Iii: Preparation and Standardization of Inoculums: 
A total of 60 Candida isolates representing all the 
species identified were used for the test, as follows: 
Candida albicans                                                  n=39  
Candida glabrata                                                  n=8 
Candida tropicalis                                                n=4  
Candida krusei                                                     n=5 
Candida dubliniensis                                           n=4 
Candida albicans ATCC 10231 (control organism). 
Prior to testing, all isolates were sub-cultured on SDA 
plates and incubated overnight at 370C to ensure 
purity and viability. Approximately five isolated 
colonies were picked and then suspended in sterile 
saline and homogenized; the turbidity of the 
suspension was adjusted to match that of a Mac 
Farland 0.5 turbidity standard using a 
spectrophotometer. 
iv. Inoculation of Plates: 
The surface of the prepared SDA plates were dried at 
370C in the oven and each plate was divided into four 
segments. Each of the segments was inoculated with a 
loopful (0.01ml) of the standardized suspension of the 
organism. The organism was also inoculated into 
control plates (drug free). 
v. Determination of MIC: 
After 24hrs incubation at 370C, the amount of growth 
in the plates containing the different concentrations of 
antifungal agents was compared with the amount of 
growth in the drug- free growth control plates. The 
MIC was read as the lowest concentration of 
antifungal that totally inhibited the growth of the 
organism. 
INTERPRETATIVE CRITERIA 
The interpretation of the results was based on the 
break points [9] established by the National 
Committee for Clinical Laboratory Standards 
(NCCLS) for different antifungal drugs against 
Candida species [Table 2].  
 
TABLE 2: MIC BREAKPOINTS FOR SUSCEPTIBILITY OF CANDIDA TO ANTIFUNGAL DRUGS 
Interpretation of MIC Values 
     Drug                         Susceptible                    Intermediate(SDD)                       Resistant 
Fluconazole               ≤ 8µg/ml                           16-32µg/ml                                   >64µg/ml 
           Miconazole/  Cotrimazole            ≤ 0.5µg/ml                            1-4 µg/ml                                              >8µg/ml 
Itraconazole             ≤ 0.125µg/ml                  0.25-0.5 µg/ml                                   > 1µg/ml 
Key : S – D D =  Dose dependent susceptibility 
STATISTICAL ANALYSIS   
Statistical analysis: Chi square test, One way Analysis 
of Variance(ANOVA) and t- test conclude and 
validate the results at 0.05 level of significance. 
RESULT 
Yeasts cells were seen as a small, oval cell, measuring 
2-4 in diameter that were budding or single. 
Following clinico-mycological evaluation of  the 
patients, 73%, 67%, 50% and 50% of patients on 
Fluconazole, Miconazole, Clotrimazole and 
Itraconazole respectively were symptomatically 
relieved while 91%, 89%, 88% and 17% of patients on 
Fluconazole, Miconazole, Clotrimazole and 
Itraconazole respectively were mycologically relieved 
at 2 weeks after treatment [Table 3]. The rate of 
mycological resolution was higher than symptomatic 








TABLE 3: CLINICO -MYCOLOGICALLY EVALUATION AT 2 WEEKS AFTER TREATMENT WITH ANTIFUNGAL DRUGS. 
                                        A                 B                   C                  D 
Drug                    Number             Very Good         Good             Fair            Poor            Score 
                                                              Admitted 
Fluconazole            11                          7                      3                     1                0                   28 
Miconazole              9                           5                      3                     1                0                   22 
Clotrimazole           8                           3                      4                     1                1                   18 
Itraconazole           14                         6                       4                     1                3                   17 
 
The following rating scales were used: A. Symptom absent, culture negative  =  Very good =3 point score; B.    Symptom present, 
culture negative  =  Good  = 2 point score; C.   Symptom absent, culture positive = Fair = 1 point score;   D.   Symptom present, 
culture positive = Poor= Zero point score 
 
TABLE 4:  SYMPTOMATIC RELIEF AND MYCOLOGICAL CURE RATES AT 2WEEKAFTER TREATMENT WITH 
ANTIFUNGAL DRUGS 
             Drug                                             Symptomatic relief                              Mycological cure 
Fluconazole                                         8 (73%)                                                10 (91%) 
Miconazole                                          6 (67%)                                                  8 (89%) 
Clotrimazole                                       4 (50%)                                                  7 (88%) 
Itraconazole                                        7 (50%)                                                 10 (71%) 
Mycological vs symptomatic relief at 2 weeks (t = 6.91 ;< 0.05) 
The minimum inhibitory concentration (MIC) of 
Antifungal agents against Candida species isolated 
from women with vulvovaginal candidiasis was done 
using the interpretative criteria on Table 1. The 
susceptibility testing of 60 Candida isolates 
(representing different species) to fluconazole (C. 
albicans, C. tropicalis, C. dubliniensis, C. krusei and C. 
glabrata) showed varied degree of susceptibility. Of 
the 60 isolates, 52 (86.7%) were susceptible (MIC< 8 
mg/ml) to fluconazole whereas, 8 (13.3%) isolates 
were intermediate with MIC 16-32 mg/ml. There was 
no record of resistance with fluconazole in this study 
[Table 5].  Of the 8 isolates with elevated MIC, 4 
isolates were Candida glabrata, 1 isolate was Candida 
tropicalis, 2 isolates were Candida krusei and 1isolate 
Candida albicans.  All the 60 Candida isolates (100%) 
had very low MIC to Miconazole and Cotrimazole (< 
0.5 µg/m1) [Table 6]. On the contrary, only 26 (43%) 
of the isolates were susceptible to Itraconazole (MIC 
<0.125 µg/m1), whereas 21 (35%) were resistant 
(MIC>1µg/m1), while 13 (22%) showed dose 
dependent susceptibility to the drug. Among all the 
species, the most resistant was the C. tropicalis which 
recorded 100% resistance to Itraconazole, followed by 
C. krusei which has about 40% resistance. [Table 7]. 







TABLE 5: MINIMUM INHIBITORY CONCENTRATION OF FLUCONAZOLE ON CANDIDA SPECIES ISOLATED FROM 
VULVOVAGINAL CANDIDIASIS PATIENTS IN ANAMBRA STATE 
                                                                                            MIC (µg/ml) 
Candida species                              ≤ 8 µg /ml              16-32 µg/ml                ≥ 64µg/ml 
                                                         (Susceptible)        (Intermediate)           (Resistance) 
Candida albicans                                 38/39                          1/39                                       0/39 
Candida tropicalis                                  ¾                                 ¼                                       0/4 
Candida dubliniensis                             4/4                              0/4                                        0/4 
Candida krusei                                        3/5                              2/5                                        0/4 
Candida glabrata                                   4/8                               4/8                                        0/4 
Total (%)                                              52/60 (86.7%)           8/60 (13.3%)                           0/60 (0%) 
 
                TABLE 6: MIC OF MICRONAZOLE / CLOTRIMAZOLE AMONG CANDIDA SPECIES 
                                                                                            MIC (µg/ml) 
Candida species                              ≤ 0.5 µg /ml                                                             ≥ 8µg/ml 
                                                         (Susceptible)                                                          (Resistance) 
Candida albicans                                 39/39                                                                      0/39 
Candida tropicalis                                 4/4                                                                         0/4 
Candida dubliniensis                             4/4                                                                         0/4 
Candida krusei                                        5/5                                                                        0/5 
Candida glabrata                                   8/8                                                                         0/8 
Total (%)                                              60/60 (100%)                                                    0/60 (0%) 
 
TABLE 7: MINIMUM INHIBITORY CONCENTRATION OF ITRACONAZOLE ON CANDIDA SPECIES                                         
ISOLATED FROM VULVOVAGINAL CANDIDASIS PATIENTS IN ONITSHA, ANAMBRA STATE 
                                                                                            MIC (µg/ml) 
Candida species                              ≤0.125 µg /ml         0.25-0.5 µg/ml                         ≥ 1µg/ml 
                                                         (Susceptible)           (Intermediate)                       (Resistance) 
Candida albicans                                 19/39                          8/39                                       12/39 
Candida tropicalis                                 0/4                             0/4                                            4/4  
Candida dubliniensis                            0/4                              1/4                                           1/4 
Candida krusei                                       2/5                              1/5                                           2/5 
Candida glabrata                                  2/8                              3/8                                           2/8 




The study compares the antifungal susceptibility 
patterns of 4 antifungal drugs against isolated Candida 
species. The antimicrobial susceptibility testing in this 
study revealed that most non albicans were resistant 
to Itraconazole.  None of the candida isolates tested 
were resistant to Miconazole, Clotrimazole and 
Fluconazole, although susceptibility of 14% of the 
isolates to fluconazole was dose dependent (S-DD), 
and majority 7/8 (88%)   of these (S-DD) were non- 
albicans Candida (Candida glabrata and Candida 
krusei). The extensive use of Fluconazole leads to a 
shift in the causative agents of Candida infections to 
non-albicans species such as C.glabrata, C.krusei and 
C.tropicalis [10]. Although the efficacy of the drugs 
could not be established on the basis of the invitro 
susceptibility report since there was a degree of 
variability in the MIC values within the class of 
antifungals. Fluconazole, Miconazole and 
Clotrimazole appears to be the best choice, while 
Itraconazole due to its lower efficacy against non-
albicans candida would be a poor choice in the blind 
treatment of vulvovaginal candidiasis in this locality 
as non-albicans are increasingly important participant 
in vulvovaginal candidiasis in this locality.  
A recent study by Kiguli et al.,[11] described C. krusei 
with a high resistance of 71.43% to fluconazole 
whereas C. glabrata, and C. krusei exhibited 100% 
resistance and C. albicans exhibiting 20.59% to 
itraconazole. Resistance to clotrimazole was observed 
in 36.67% and 0.61% of C. glabrata and C. albicans 
respectively.  Resistance to clotrimazole and 
fluconazole does not correlate with our study that 
revealed 0% resistance respectively by all Candida 
species. While, resistance to itraconazole by C.glabrata, 
C.krusei and C.albicans partially agrees with reports 
from our study which revealed 20%, 40% and 30.8% 
resistance to itraconazole by C.glabrata, C.krusei and 
C.albicans respectively. 
Dharmik et al., [12] revealed that fluconazole was 
highly effective against Candida Species (97.2 %) while, 
the highest resistance was observed in the case of 
miconazole (63 %). This is contrary to our study that 
observed highest resistance to itraconazole (35%). 
Resistance to itraconazole was observed in 16.2% 
(MIC ≥ 1 µg/ml). Among different species, elevated 
fluconazole MICs (≥16 µg/ml) were only observed in 
C. glabrata (15.2% resistant [R], 51.8% susceptible-dose 
dependent [S-DD]), and C. krusei (50% S-DD, 41.7% R, 
considered intrinsically fluconazole resistant). 
Resistance to itraconazole was observed among C. 
glabrata (74.1%) and C. krusei (58.3%). These results by 
Richter et al., [13] support that of this study which 
showed resistance to itraconazole ((MIC ≥ 1 µg/ml) 
among C. glabrata (20%) and C. krusei (40%). 
Furthermore, supports elevated fluconazole MICs (16-
32 µg/ml) observed more frequently among 
C.glabrata, C.krusei, C.tropicalis and C.albicans. Thus, 
fluconazole resistance among vaginal Candida albicans 
isolates is emerging.  
 
Comparison of symptomatic relief and mycological 
cure rate at second week after treatment with 
Fluconazole, Miconazole, Clotrimazole and 
Itraconazole shows that the rate of mycological cure 
was significantly more than the symptomatic relief 
(t=6.91; p < 0.05). The time required by the body to 
recover after the annihilation of the infecting 
organism could be a contributing factor. Hence, the 
use of azoles for empirical therapy of uncomplicated 
Vulvovaginal candidiasis is recommended. 
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